If they fit the parameters for a BMI and they lose 10 to 20 pounds and theyre losing weight and theyre getting off other medications, then I cant disagree with that if they met the parameters beforehand, but if somebodys below the parameters, like significantly below 27 BMI without other obesity related diseases, then we wouldnt be prescribing it because that would be considered off label, but its not illegal
Conversely, even modest weight loss, around 5%, can enhance heart and blood sugar health, with greater weight loss, ideally exceeding 10%, yielding even more significant benefits
The primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning insulin is only released when blood glucose levels are elevated Suppressing glucagon release from pancreatic alpha cells, which reduces hepatic glucose production Slowing gastric emptying , which helps moderate post-meal blood glucose spikes Reducing appetite through central nervous system effects, leading to decreased caloric intake and weight loss Examples of GLP-1 receptor agonists available in the UK include exenatide (Byetta, Bydureon), liraglutide (Victoza for diabetes, Saxenda for weight management), dulaglutide (Trulicity), lixisenatide (Lyxumia), and semaglutide (Ozempic/Rybelsus for diabetes, Wegovy for weight management)
Beam WB, Hunter Guevara LR
It differs from other weight-loss drugs, such as semaglutide and tirzepatide, because it is a first-in-class triple agonist that targets three hormones: GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon
